^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Kinenza (enzastaurin)

    i
    Company:
    Aytu BioPharma, Denovo
    Drug class:
    PI3K inhibitor, AKT inhibitor, PKCβ inhibitor
    Related drugs:
    Apply
    A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1 (ENGAGE) (NCT03776071)
    Phase 3
    Denovo Biopharma LLC
    Completed
    Last update posted :
    04/22/2024
    Initiation :
    12/16/2020
    Primary completion :
    02/29/2024
    Completion :
    02/29/2024
    MGMT
    |
    MGMT promoter methylation
    |
    temozolomide • Kinenza (enzastaurin)
    Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ (NCT03263026)
    Phase 3
    Denovo Biopharma LLC
    Completed
    Last update posted :
    08/01/2022
    Initiation :
    03/20/2018
    Primary completion :
    07/12/2022
    Completion :
    07/12/2022
    BCL2 • CD20 • BCL6
    |
    CD20 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Kinenza (enzastaurin)
    A Study for Patients With Non-Hodgkin's Lymphomas (NCT00542919)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    10/19/2020
    Initiation :
    11/01/2007
    Primary completion :
    03/01/2010
    Completion :
    02/27/2018
    CD4 • DPP4
    |
    Kinenza (enzastaurin)
    Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") (NCT00391118)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    10/19/2020
    Initiation :
    11/01/2006
    Primary completion :
    04/01/2010
    Completion :
    07/01/2012
    PTEN • MUC16 • GSK3B • PRKCB
    |
    carboplatin • paclitaxel • Kinenza (enzastaurin)
    A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas. (NCT00042666)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    08/10/2020
    Initiation :
    06/01/2002
    Primary completion :
    09/01/2008
    Completion :
    09/01/2008
    PRKCB
    |
    Kinenza (enzastaurin)
    Enzastaurin for Patients With Metastatic Colorectal Cancer (NCT00192114)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    08/06/2020
    Initiation :
    08/01/2005
    Primary completion :
    03/01/2008
    Completion :
    03/01/2008
    CEACAM5
    |
    Kinenza (enzastaurin)
    Chemotherapy for Participants With Lymphoma (NCT00436280)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    08/06/2020
    Initiation :
    02/01/2007
    Primary completion :
    11/01/2009
    Completion :
    11/01/2012
    CD20 • PRKCH • PRKCB
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Kinenza (enzastaurin)
    Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma (NCT00088205)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    07/01/2020
    Initiation :
    03/01/2004
    Primary completion :
    05/01/2008
    Completion :
    05/01/2008
    PRKCH • PRKCB
    |
    Kinenza (enzastaurin)
    Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma (NCT00509821)
    Phase 2
    Eli Lilly and Company
    Completed
    Last update posted :
    04/05/2019
    Initiation :
    10/01/2007
    Primary completion :
    02/01/2010
    Completion :
    03/01/2016
    GSK3B
    |
    Kinenza (enzastaurin)
    PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin (NCT00332202)
    Phase 3
    Eli Lilly and Company
    Completed
    Last update posted :
    09/10/2018
    Initiation :
    06/01/2006
    Primary completion :
    04/01/2013
    Completion :
    07/01/2013
    PRKCB • EFS
    |
    Kinenza (enzastaurin)